Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
|Videos|August 19, 2022
Advice from a Raindrop
Author(s)Richard M. Berlin, MD
"You think you’re too small to make a difference?"
Advertisement
Any Good Poem
Richard Berlin, MD, shares the poem "
Dr Berlin has been writing a poem about his experience of being a doctor every month for the past 24 years in Psychiatric Times™ in a column called “Poetry of the Times.” He is instructor in psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts. His latest book is
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
2
New Adult ADHD Guidelines: What Resources Are Coming Soon
3
Vol 43, Issue 9 - Interactive
4
What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice
5